Trial Profile
Safety and efficacy of sorafenib in patients with metastatic medullary thyroid cancer: A retrospective longitudinal study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Feb 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 23 Feb 2017 New trial record